Categorynews

Tarveda Therapeutics to Present Nonclinical Data on PEN-221 in Combination with Epigenetic Modulation at the 2019 AACR Annual Meeting

March 26, 2019 Off By BusinessWire

– Data demonstrate how an HDAC inhibitor increases the tumor expression
of SSTR2 with synergy of efficacy –

WATERTOWN, Mass.–(BUSINESS WIRE)–Tarveda
Therapeutics, Inc., a clinical stage biopharmaceutical company
discovering and developing a new class of potent and selective miniature
drug conjugates (Pentarins®) for the treatment of patients with a wide
range of solid tumors, today announced that the company will present
nonclinical data on PEN-221 at the 2019 American Association for Cancer
Research (AACR) Annual Meeting, occurring March 29 – April 3, 2019 in
Atlanta, GA.

PEN-221 is a miniature drug conjugate designed to rapidly penetrate deep
into solid tumors where it is highly selective for somatostatin receptor
2 (SSTR2) and accumulates its potent DM1 cytotoxic payload. The
presenter will demonstrate the effectiveness of PEN-221 in combination
with epigenetic modulation by an HDAC inhibitor in nonclinical models of
human cancer. The data show that an HDAC inhibitor increases the tumor
expression of SSTR2 with synergy of efficacy.

Details of the poster presentation are as follows:

Title: Epigenetic modulation of SSTR2 expression provides the
potential to broaden PEN-221 treatment population
Date:
Tuesday, April 2, 2019
Time: 1:00pm Eastern Time
Location:
Georgia World Congress Center, Atlanta, GA

About Tarveda Therapeutics, Inc.

Tarveda Therapeutics, Inc. is discovering and developing a new class of
potent and selective miniature drug conjugates (Pentarins®) for the
treatment of patients with a wide range of solid tumors. PEN-221 is a
miniature drug conjugate in clinical evaluation for the treatment of
patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine,
small cell lung and other solid tumors. PEN-221 is highly selective for
SSTR2 and is designed to rapidly penetrate deep into solid tumors where
it accumulates and releases its potent DM1 payload over time within the
tumor cells. Tarveda is also advancing its HSP90 binding drug conjugate
platform with lead drug candidate PEN-866, which selectively binds in
tumors to the activated form of Heat Shock Protein 90 (HSP90) and
releases its potent topoisomerase 1 inhibitor payload, SN38. The safety
and efficacy of PEN-866 in patients with cancer is currently being
evaluated in a clinical trial. Tarveda’s strategy includes developing
its own proprietary miniature drug conjugates as well as applying its
miniature drug conjugate platform to enhance the effectiveness of the
targeting moieties and novel payloads of pharmaceutical collaborators. www.tarvedatx.com